AgomAb Therapeutics

(NASDAQ) AGMB

Current Price$17.44

Market Cap$673.06M

Since IPO (2026)-6%

5 YearN/A

1 YearN/A

1 Month+18%

AgomAb Therapeutics Financials at a Glance

Market Cap

$673.06M

Revenue (TTM)

€0.00

Net Income (TTM)

-€32.77

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-0.13 (Low)

Dividend

$0.00

Beta (Volatility)

-0.13 (Low)

Price

$17.44

Volume

6,306

Open

$14.24

Price

$17.44

Volume

6,306

Open

$14.24

Previous Close

$17.44

Daily Range

$14.22 - $17.49

52-Week Range

$8.75 - $17.49

Estimated Earnings Date

Sep 2, 2026

Dividend

$0.00

Beta (Volatility)

-0.13 (Low)

Price

$17.44

Volume

6,306

Open

$14.24

Previous Close

$17.44

Daily Range

$14.22 - $17.49

52-Week Range

$8.75 - $17.49

Estimated Earnings Date

Sep 2, 2026

AGMB News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About AgomAb Therapeutics

Industry

Pharmaceuticals

Sector

Health Care

Employees

CEO

Tim Knotnerus, PhD

Website

agomab.com

Headquarters

Antwerp, 2600, BE

AGMB Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-20.97%

Return on Capital

-44.85%

Return on Assets

-18.95%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$673.06M

Shares Outstanding

48.74M

Volume

6.31K

Avg. Volume

132.79K

Financials (TTM)

Gross Profit

€0.00

Operating Income

-€28.34M

EBITDA

-€29.42M

Operating Cash Flow

-€25.61M

Capital Expenditure

-€367.00K

Free Cash Flow

-€25.98M

Cash & ST Invst.

€116.51M

Total Debt

€1.25M

AgomAb Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

€0.00

N/A

Gross Profit

€0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$673.06M

N/A

Market Cap/Employee

$11.81M

N/A

Employees

N/A

Net Income

-€17.40M

N/A

EBITDA

-€17.62M

N/A

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Total Cash

€116.51M

N/A

Total Debt

€1.25M

N/A

Accounts Receivable

€4.09M

N/A

Inventory

€0.00

N/A

Long Term Debt

€1.01M

N/A

Short Term Debt

€249.00K

N/A

Return on Assets

-18.95%

N/A

Return on Invested Capital

-20.98%

N/A

Free Cash Flow

-€13.18M

N/A

Operating Cash Flow

-€13.17M

N/A

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

^GSPCS&P 500

^GSPCS&P 500$7,431.57+0.01%

^DJIDJI

^DJIDJI$52,226.51+0.01%

^IXICNASDAQ

^IXICNASDAQ$25,747.06+0.02%

BTCBitcoin

BTCBitcoin$60,361.00+0.01%

SPCXSPCX

SPCXSPCX$160.10+0.04%

AAPLAAPL

AAPLAAPL$281.43-0.01%

AMZNAMZN

AMZNAMZN$240.22+0.03%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

CMCSAComcast

CMCSAComcast$24.22+0.05%

AALAmerican Airlines Group

AALAmerican Airlines Group$17.92+0.00%

SMCISuper Micro Computer

SMCISuper Micro Computer$28.15-0.08%

TAT&T

TAT&T$21.82-0.04%

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$164.19+0.07%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$13.64+0.17%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$77.19+0.07%

Questions About AGMB

What is the current price of AgomAb Therapeutics?

AgomAb Therapeutics is trading at $17.44 per share.

What is the 52-week range for AgomAb Therapeutics?

Over the past 52 weeks, AgomAb Therapeutics has traded between $8.75 and $17.49.

How much debt does AgomAb Therapeutics have?

As of the most recent reporting period, AgomAb Therapeutics reported total debt of €1.47M.

How much cash does AgomAb Therapeutics have on hand?

AgomAb Therapeutics reported €101.49M in cash and cash equivalents in its most recent financial results.

What is AgomAb Therapeutics’s dividend yield?

AgomAb Therapeutics does not currently have a dividend yield.

AgomAb Therapeutics

AgomAb Therapeutics Financials at a Glance

AGMB News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About AgomAb Therapeutics

AGMB Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

AgomAb Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About AGMB

What is the current price of AgomAb Therapeutics?

What is the 52-week range for AgomAb Therapeutics?

How much debt does AgomAb Therapeutics have?

How much cash does AgomAb Therapeutics have on hand?

What is AgomAb Therapeutics’s dividend yield?

Premium Investing Services